Results 51 to 60 of about 46,511 (209)

Structural and molecular characterization of lopinavir and ivermectin as breast cancer resistance protein (BCRP/ABCG2) inhibitors

EXCLI Journal : Experimental and Clinical Sciences, 2023
A current clinical challenge in cancer is multidrug resistance (MDR) mediated by ABC transporters. Breast cancer resistance protein (BCRP) or ABCG2 transporter is one of the most important ABC transporters implicated in MDR and the use of inhibitors is a
Julia de Paula Dutra, Gustavo Scheiffer, Thales Kronenberger, Lucas Julian Cruz Gomes, Isadora Zanzarini, Kelly Karoline dos Santos, Arun K. Tonduru, Antti Poso, Fabiane Gomes de Moraes Rego, Geraldo Picheth, Glaucio Valdameri, Vivian Rotuno Moure   +11 more
doaj   +1 more source

Safety and Effectiveness of Glecaprevir/Pibrentasvir in Children and Adolescents With Chronic Hepatitis C: Reports From All‐Case Post‐Marketing Surveillance in Japan

Hepatology Research, EarlyView.
ABSTRACT Aim The aim of this all‐case post‐marketing study was to evaluate the real‐world safety and effectiveness in all children and adolescents with chronic hepatitis C with or without compensated cirrhosis treated with glecaprevir/pibrentasvir (G/P) in Japan. Methods This prospective, observational post‐marketing surveillance study was conducted at
Tatsuki Mizuochi, Katsuyoshi Kawana, Mariko Kobayashi, Eri Iwashita, Itaru Iwama, Daiki Abukawa, Hitoshi Tajiri   +6 more
wiley   +1 more source

Structural multiplicity in a solvated hydrate of the antiretroviral protease inhibitor Lopinavir

Acta Crystallographica Section E: Crystallographic Communications
Lopinavir is a potent protease inhibitor that is used as a first-line pharmaceutical drug for the treatment of HIV. The multi-component solvated Lopinavir crystal, systematic name (2S)-N-[(2S,4S,5S)-5-[2-(2,6-dimethylphenoxy)acetamido]-4-hydroxy-1,6 ...
Tebogo M. L. Mokoto, Andreas Lemmerer, Yasien Sayed, Mark G. Smith   +3 more
doaj   +1 more source

Determination of lopinavir/ritonavir concentrations in four different oral solutions for the application of antiretroviral therapy in very young, HIV-1-infected children

Southern African Journal of HIV Medicine, 2021
No abstract available.
Nils von Hentig, Carlo Angioni, Christoph Königs   +2 more
doaj   +1 more source

The impact of accumulating immune adaptation in circulating strains of HIV‐1

HIV Medicine, EarlyView.
Abstract Background Mutations in human immunodeficiency virus type 1 (HIV‐1) enable the virus to evade recognition and killing by human leucocyte antigen (HLA)‐restricted T cells. These viral adaptations are specific to the HLA type of individuals and are therefore evident as HLA allele‐HIV sequence associations at the population level. Most studies of
Marwah Al‐kaabi, Alison Castley, Pooja Deshpande, Abha Chopra, David Nolan, Simon Mallal, Mina John, Silvana Gaudieri   +7 more
wiley   +1 more source

Virological outcomes of second-line protease inhibitor-based treatment for human immunodeficiency virus type 1 in a high-prevalence rural South African setting: a competing-risks prospective cohort analysis [PDF]

, 2017
Background. Second-line antiretroviral therapy (ART) based on ritonavir-boosted protease inhibitors (bPIs) represents the only available option after first-line failure for the majority of individuals living with human immunodeficiency virus (HIV ...
2LADY Study Group, Alexandra Calmy, Anne Derache, ANRS 12249 TasP Study Group, Collins Iwuji, Dami Collier, DART Virology Group and Trial Team, Deenan Pillay, EARNEST Trial Team, Francois Dabis, National Department of Health, National Department of Health, Nonhlanhla Okesola, PharmAccess African Studies to Evaluate Resistance (PASER), PharmAccess African Studies to Evaluate Resistance (PASER), Ravindra K. Gupta, SECOND-LINE, SECOND-LINE Study Group, Southern African Treatment and Resistance Network, TenoRes Study Group, Tulio de Oliveira, World Health Organization, World Health Organization   +22 more
core   +3 more sources

Evaluation of the efficacy and safety of oral N‐acetylcysteine in patients with COVID‐19 receiving the routine antiviral and hydroxychloroquine protocol: A randomized controlled clinical trial

Immunity, Inflammation and Disease, 2023
Background The current absence of gold‐standard or all‐aspect favorable therapies for COVID‐19 renders a focus on multipotential drugs proposed to prevent or treat this infection or ameliorate its signs and symptoms vitally important.
Najmolsadat Atefi, Azadeh Goodarzi, Taghi Riahi, Niloofar Khodabandehloo, Mahshid Talebi Taher, Niloufar Najar Nobari, Farnoosh Seirafianpour, Zeinab Mahdi, Amir Baghestani, Rohollah Valizadeh   +9 more
doaj   +1 more source

Longitudinal changes in plasma biomarkers of immune activation, neuronal inflammation and injury in persons with HIV initiating ART

HIV Medicine, EarlyView.
Abstract Background Data on changes in biomarkers of brain health, and their associations with cognitive function in adults commencing either dual‐ or triple‐antiretroviral therapy (ART) are sparse. Methods Plasma biomarkers (neurofilament light [NfL], glial fibrillary acidic protein [GFAP], sCD14, CXCL10, neopterin and IL‐6) were measured at baseline ...
Merle Henderson, Peter Dutey‐Magni, Carolina Herrera, Wolfgang Stöhr, Alejandro Arenas‐Pinto, Owen Swann, Amanda Heslegrave, Henrik Zetterberg, John Tregoning, Sarah Fidler, François Raffi, Andrea Calcagno, Ab Babiker, Alan Winston   +13 more
wiley   +1 more source

Antenatal atazanavir: a retrospective analysis of pregnancies exposed to atazanavir. [PDF]

, 2014
INTRODUCTION: There are few data regarding the tolerability, safety, or efficacy of antenatal atazanavir. We report our clinical experience of atazanavir use in pregnancy.
Anderson, J, Bradshaw, D, Brook, G, Byrne, L, Chan, SY, de Ruiter, A, Dhairyawan, R, Hawkins, D, Hay, P, Mandalia, S, Naftalin, C, Natha, M, Noble, H, Offodile, N, Perry, M, Poulton, M, Rodgers, M, Roedling, S, Samuel, M, Sarner, L, Shah, R, Short, CE, Smith, K, Taylor, G, Zhou, J   +24 more
core   +2 more sources

Current Clinical Trials and Vaccine Development Strategies for Corona Virus Disease (COVID-19)

Journal of Pure and Applied Microbiology, 2020
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has reached global epidemic status claiming more than 319K lives and affecting more than 4.81M people and counting worldwide.
Abhi Bhadra, Shweta Singh, Shaswat Chandrakar, Vanshika Kumar, Sakshi Sankhla, Sayuj Raj T., E. Selvarajan   +6 more
doaj   +1 more source